{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=3&q=Hodgkin", "query": { "q": "Hodgkin", "condition": "Lymphoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 3802, "total_pages": 381, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=4&q=Hodgkin&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=2&q=Hodgkin&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T14:15:09.796Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02192021", "title": "Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T Cell Lymphoma" ], "interventions": [ { "name": "Micro needle array-Doxorubicin (MNA-D)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Falo, Louis, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-03-09", "completion_date": "2020-12-09", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192021" }, { "nct_id": "NCT01254578", "title": "Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A", "Adult Acute Promyelocytic Leukemia With PML-RARA", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-Cell Lymphoma", "Alkylating Agent-Related Acute Myeloid Leukemia", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-Cell Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Hepatosplenic T-Cell Lymphoma", "Intraocular Lymphoma", "Lymphomatous Involvement of Non-Cutaneous Extranodal Site", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Nodal Marginal Zone Lymphoma", "Post-Transplant Lymphoproliferative Disorder", "Primary Cutaneous B-Cell Non-Hodgkin Lymphoma", "Prolymphocytic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Richter Syndrome", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "T-Cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-11-24", "completion_date": "2012-11-09", "has_results": false, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01254578" }, { "nct_id": "NCT01598025", "title": "Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Leukemia", "Chronic Leukemia", "Myelodysplastic Syndrome", "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "total-body irradiation (TBI)", "type": "RADIATION" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "19 Years", "sex": "ALL", "summary": "Up to 19 Years" }, "enrollment_count": 3, "start_date": "2012-05-02", "completion_date": "2017-10-16", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598025" }, { "nct_id": "NCT05798897", "title": "Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma, Adult", "Non-Hodgkin Lymphoma, Refractory", "Non-Hodgkin Lymphoma, Relapsed", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Hodgkin Lymphoma, Adult", "Hodgkin's Lymphoma, Relapsed, Adult" ], "interventions": [ { "name": "MT-601", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marker Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 79, "start_date": "2023-01-02", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 7, "location_summary": "Duarte, California • Aurora, Colorado • Denver, Colorado + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05798897" }, { "nct_id": "NCT04752826", "title": "BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Ovarian Cancer", "T-cell Lymphoma", "Melanoma" ], "interventions": [ { "name": "BI-1808", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection", "type": "DRUG" }, { "name": "Paclitaxel 80 mg/m2 weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioInvent International AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2021-01-25", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752826" }, { "nct_id": "NCT01132989", "title": "Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T Cell Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Florida Academic Dermatology Centers", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2010-05", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2010-05-28", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132989" }, { "nct_id": "NCT04334174", "title": "Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-05-29", "completion_date": "2023-02-01", "has_results": false, "last_update_posted_date": "2023-02-03", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04334174" }, { "nct_id": "NCT00014560", "title": "Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "bispecific antibody 4G7xH22", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2000-09-28", "completion_date": "2003-02-14", "has_results": true, "last_update_posted_date": "2018-05-03", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014560" }, { "nct_id": "NCT03696784", "title": "Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Lymphoma, B-Cell", "Immune System Diseases", "Immunoproliferative Disorders", "Lymphatic Diseases" ], "interventions": [ { "name": "iC9-CAR19 T cells", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "AP1903", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-03-12", "completion_date": "2040-07-31", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03696784" }, { "nct_id": "NCT00733824", "title": "Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Hodgkin Disease" ], "interventions": [ { "name": "AMD3100", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 61, "start_date": "2008-11", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-10T14:15:09.796Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00733824" } ] }